William C. Huang, MD, highlights data from a long-term extension study of the OPTIMA II trial. In a recent interview with Urology Times®, William C. Huang, MD, outlined the key findings and ...

IDE397 combined with sacituzumab govitecan showed promising efficacy in MTAP-deletion urothelial carcinoma, with high disease control rates in both dose cohorts. The combination therapy's efficacy ...

Cretostimogene grenadenorepvec shows a 24-month complete response rate of 41.8% in high-risk BCG-unresponsive NMIBC patients, with 90% of 12-month responders maintaining CR. The BOND-003 trial ...

David Stanley, MD, FACS, discusses current trends and unmet needs in the treatment of patients with kidney stones. In a recent interview with Urology Times®, David Stanley, MD, FACS, discussed current ...

Prostate cancer awareness is crucial year-round, emphasizing screening and meaningful conversations about risk and prevention. Screening guidelines vary, focusing on shared decision-making and ...

The survey examines urologists' treatment patterns and preferences for non–muscle invasive bladder cancer, providing valuable insights into current practices. Michael S. Cookson, MD, and Jason M.

Nivolumab plus ipilimumab improved overall survival and response rates over sunitinib in advanced renal cell carcinoma, with a median follow-up of 9.3 years. The combination showed sustained benefits ...

UGN-102's NDA is supported by the phase 3 ENVISION trial, showing a 79.6% complete response rate at 3 months for LG-IR-NMIBC patients. The FDA is evaluating if the observed duration of response is due ...

Cytoreductive nephrectomy (CN) remains vital in mRCC management, with immune checkpoint inhibitors (ICI) reshaping treatment strategies and patient selection criteria. The SCREEN score offers superior ...

Risk Stratification Systems: The panel discussed various risk classification systems for non–muscle-invasive bladder cancer (NMIBC), comparing AUA, EU, and international bladder cancer group ...

In this episode, guideline chair Melissa Kaufman, MD, PhD, FACS, highlights key points from the new AUA GSM guideline and illustrates its impact for clinical ...

Cretostimogene grenadenorepvec achieved a 75.5% complete response rate in high-risk, BCG-unresponsive NMIBC patients, with 97% remaining progression-free. The phase 3 BOND-003 trial demonstrated ...